Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDFT1 | P37268 | 11/20 | 0.48 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.35 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | ENO1 | P06733 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8824807 | 0.89 | FDFT1 (0.53) | FDFT1 | |
| SCHEMBL762953 | 0.89 | FDFT1 (0.53) | FDFT1 | |
| SCHEMBL16366775 | 0.85 | FDFT1 (0.48) | FDFT1 | |
| SCHEMBL12873126 | 0.84 | FDFT1 (0.48) | FDFT1 | |
| SCHEMBL13552731 | 0.78 | FDFT1 (0.49) | FDFT1 | |
| SCHEMBL8897781 | 0.77 | FDFT1 (0.50) | FDFT1 | |
| SCHEMBL8897991 | 0.77 | FDFT1 (0.50) | FDFT1 | |
| SCHEMBL14106669 | 0.77 | FDFT1 (0.48) | FDFT1 | |
| SCHEMBL8897832 | 0.76 | FDFT1 (0.49) | FDFT1 | |
| SCHEMBL10066424 | 0.76 | FDFT1 (0.63) | FDFT1MTNR1AMTNR1BMMP2MMP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2195322-B1 | IMIDAZO[1,2-A]PYRIMIDINE DERIVATIVES FOR TREATING DISEASES SUCH AS DIABETES | MERCK PATENT GMBH (DE) | 2014-08-06 | — | — | EP | disclosed |
| EP-2089387-B1 | INDOLIZINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS | MERCK PATENT GMBH (DE) | 2013-10-23 | — | — | EP | disclosed |
| US-8399509-B2 | Glucopyranoside derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-03-19 | — | — | US | disclosed |
| US-8399509-B2 | Glucopyranoside derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2013-03-19 | — | — | US | disclosed |
| EP-2260051-B1 | GLUCOPYRANOSIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2012-10-17 | — | — | EP | disclosed |
| US-8278312-B2 | Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8278312-B2 | Imidazo 1,2-a pyrimidine derivatives for the treatment of diseases such as diabetes | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-8258151-B2 | 3-aminoimidazo [1,2-A] pyridine derivatives as SGLT inhibitors | MERCK PATENT GMBH (DE) | 2012-09-04 | — | — | US | disclosed |
| US-8153649-B2 | 3-aminoimidazo 1,2-A pyridine derivatives having an SGLT1- and SGLT2-inhibiting action for the treatment of type 1 and type 2 diabetes | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2012-04-10 | — | — | US | disclosed |
| US-20100035915-A1 | INDOLIZINE DERIVATIVES AND THE USE THEREOF AS ANTIDIABETICS | MERCK PATENT GESELLSCHAFT (DE) | 2010-02-11 | — | — | US | disclosed |
| US-20100016372-A1 | Benzimidazole Derivatives | MERCK PATENT GMBH (DE) | 2010-01-21 | — | — | US | disclosed |
| US-20100016372-A1 | Benzimidazole Derivatives | MERCK PATENT GMBH (DE) | 2010-01-21 | — | — | US | disclosed |
| WO-2009124638-A1 | GLUCOPYRANOSIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2009-10-15 | — | — | WO | disclosed |
| WO-2008101586-A1 | BENZIMIDAZOLE DERIVATIVES | MERCK PATENT GMBH (DE) | 2008-08-28 | — | — | WO | disclosed |
| WO-2008071288-A1 | INDOLIZINE DERIVATIVES AND THEIR USE AS ANTIDIABETICS | MERCK PATENT GMBH (DE) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008046497-A1 | 3 -AMINO-IMIDAZO [1,2 -A] PYRIDINE DERIVATIVES HAVING AN SGLT1 AND SGLT2 INHIBITING ACTION, FOR TREATING TYPE 1 AND TYPE 2 DIABETES | MERCK PATENT GMBH (DE) | 2008-04-24 | — | — | WO | disclosed |
| US-20070299065-A1 | Tetrahydropyran Derivatives as Antidiabetics | MERCK PATENT GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| US-20070299065-A1 | Tetrahydropyran Derivatives as Antidiabetics | MERCK PATENT GMBH (DE) | 2007-12-27 | — | — | US | disclosed |
| WO-2007147478-A1 | 3 -AMINO-IMIDAZO[1, 2-A]PYRIDINE DERIVATIVES AS SGLT INHIBITORS | MERCK PATENT GMBH (DE) | 2007-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035915-A1 | INDOLIZINE DERIVATIVES AND THE USE THEREOF AS ANTIDIABETICS | GPR119, INSR, IRS1 | FDFT1 3337/4885MTNR1A 9/4885MTNR1B 18/4885 |
| US-20100016372-A1 | Benzimidazole Derivatives | GPR119, GLP1R, H1-3 | FDFT1 4458/4885MTNR1A 1397/4885MTNR1B 1225/4885 |
| US-20070299065-A1 | Tetrahydropyran Derivatives as Antidiabetics | GPR119, GLP1R, INSR | FDFT1 2578/4885MTNR1A 159/4885MTNR1B 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.